Preference, Persistency and Positioning for Lilly’s Taltz in Psoriasis Highlight a Potential Challenge Ahead for Novartis’ Cosentyx in PsO and Psoriatic Arthritis

Spherix Global Insights has released the results of two independent surveys of dermatologists (n=100) and rheumatologists (n=100) about the evolving practice patterns in the management of psoriasis (PsO) and psoriatic arthritis (PsA). Download Report Overview: Psoriasis Download Report Overview: Psoriatic Arthritis CAMBRIDGE, MASSACHUSETTS (PRWEB) APRIL 17, 2017 Despite positive perceptions, and brand expansion from the

Psoriasis and Psoriatic Arthritis Markets Undergo Big Changes as IL-17s, such as Novartis’ Cosentyx and Lilly’s Taltz, Increase Penetration

IL-17s stop Janssen's Stelara in its tracks and while Cosentyx holds out as the only approved IL-17 in PsA, competition is looming - according to a recent study by Spherix Global Insights CAMBRIDGE, Mass., April 4, 2017 /PRNewswire/ -- Spherix Global Insights has just released the results of two independent surveys of 200 rheumatologists and

Relypsa’s Veltassa Dodges the Competition Bullet as FDA Hands AstraZeneca a Second Complete Response Letter for Hyperkalemia Agent, ZS-9

Delay gives Relypsa time to close the nephrology-to-cardiology gap for Veltassa Download Report Overview March 20, 2017 – Cambridge, Massachusetts. Sixteen months and $2.7 billion ago, ZS Pharma’s hyperkalemia candidate (ZS-9, sodium zirconium cyclosilicate) was one of the most highly anticipated drugs in the renal market.  Since being acquired by AstraZeneca, the company last week

The Battle for Preferred Alternative Mechanism Biologic in Crohn’s Disease Heats Up as Launch of Janssen’s Stelara Approaches the Six-Month Mark

While gastroenterologists report a strong intent to increase future prescribing, they are quite divided about whether Stelara will displace Takeda’s Entyvio as the alternate mechanism share leader, according to the latest report by Spherix Global Insights Download Report Overview March 20, 2017 – Cambridge, Massachusetts. Spherix Global Insights has released “RealTime Dynamix: Crohn’s Disease, Q1

Will US Rheumatologists Follow in the Footsteps of Dermatologists for Adoption of Eli Lilly’s Taltz?

CAMBRIDGE, Mass., Jan. 26, 2017 /PRNewswire/ -- A recent study of 100 surveyed US rheumatologists, reveals that after viewing a product profile for the likely second to market IL-17 inhibitor for PsA, 84% anticipate prescribing Lilly's Taltz (ixekizumab), if approved. Furthermore, the vast majority of rheumatologists plan to initiate treatment within the first-year of launch.